RE: Ray Pointer18 Aug 2018 16:36
Agree with your post too, Ray. I would imagine that a company that had sunk several billion into CAR-T or similar would be unwilling to change tack to a different product, or even to consider abandoning a project on which half the company's managers and accountants had staked their reputations. But when the 'light bulb moment' comes, it is fun to watch. Think about the meeting between RG, Lindy and Keith Flaherty. Arguably a transformation event for Scancell but also for Keith Flaherty. I am sure the same will (or in the background even has already) come about for others in the world of immunotherapy.